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Abstract 
Background: New treatment options for metastasised high-grade serous carcinoma (HGSC) are urgently needed. 
HGSC frequently metastasises to the omentum, inducing angiogenesis in the local omental microvasculature to facili-
tate tumour growth. We previously showed that HGSC-secreted cathepsin L (CathL) induces pro-angiogenic changes 
in disease relevant human omental microvascular endothelial cells (HOMECs), suggesting a role in tumour angio-
genesis. Here we investigate whether CathL acts by inducing local production of the carbohydrate-binding protein 
galectin-1 (Gal1), which has been reported to be involved in tumourigenesis in other tumours.
Methods: HOMECs were used for all experiments. Gal1 mRNA and protein levels were measured by RT-PCR and 
ELISA respectively. Gal1-induced cell proliferation was assessed using WST-1 assay, migration using a transwell assay 
and in vivo Gal1 expression by immunohistochemistry.
Results: CathL transcriptionally regulated HOMEC production and secretion of Gal1 via activation of NFκB (sig-
nificantly inhibited by sulfasalazine). Gal1 significantly enhanced HOMEC migration (p < 0.001) and proliferation 
(p < 0.001), suggesting an autocrine action. The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 
and PD98059 suggesting downstream activation of this pathway. Immunohistochemical analysis of omenta from 
HGSC patients with or without metastatic disease demonstrated a positive correlation between Gal1 expression and 
number of microvessels (r = 0.8702, p < 0.001), and area of vessels (r = 0.7283, p < 0.001), supporting a proangiogenic 
role for Gal1 in omental metastases.
Conclusion: HOMEC Gal1 transcription and release in response to CathL secreted from metastasising HGSC acts in 
an autocrine manner on the local microvasculature to induce pro-angiogenic changes, highlighting a potential new 
therapeutic target.
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Background
Effective treatment of patients suffering from advanced, 
high-grade serous carcinoma (HGSC) is still clinically 
challenging [1], with development of new therapies 
impeded by our limited understanding of the cellular 
mechanisms involved in HGSC metastasis.
Primary HGSC cells commonly metastasise to the 
omentum where secondary tumour establishment 
requires local neoangiogenesis to supply oxygen and 
nutrients. This process involves activation of a proangio-
genic phenotype in the local microvascular endothelial 
cells (ECs), facilitated by complex cross-talk between the 
host omental cells and tumour cells. Growth factors and 
chemokines are locally secreted into the tumour micro-
environment and may present potential therapeutic tar-
gets. For instance, vascular endothelial growth factor 
(VEGF) is highly expressed and over-secreted in HGSC 
[2] and thus, several anti-VEGF based therapies e.g. beva-
cizumab, have been developed. However, the observation 
that these therapies have only limited benefit in advanced 
disease [3–7], and that non-VEGF pathways may play a 
role in HGSC metastasis to the omentum has raised the 
possibility that alternative pro-angiogenic factors may be 
important e.g. cathepsins D (CathD) and L (CathL) [8–
11]. It is thus important to understand the mechanisms 
by which these proteins activate angiogenic pathways in 
metastatic HGSC.
Our preliminary data suggested that CathL induces 
a differential expression of galectin1 (Gal1) mRNA 
(LGALS1) in disease-relevant human omental microvas-
cular endothelial cells (HOMECs). Gal1, a carbohydrate-
binding protein is reported to have a range of cellular 
effects [12]. In cancer, increased Gal1 expression is linked 
to tumour progression, possibly contributing to cancer 
cell invasion and metastasis formation [13, 14], and is 
associated with increased rates of disease reoccurrence 
[15–19], including in HGSC [20]. Gal1 may also play a 
role in cancer angiogenesis since Gal1 knockout mice had 
severely impeded vessel formation and disrupted tumour 
growth [21]. This is supported by the observation that, 
in  vitro, exogenous Gal1 induced angiogenic tube-for-
mation in non-disease EC models such as human umbili-
cal vein ECs (HUVECs) and EA.hy926 [22, 23]. Despite 
this emerging role for Gal1 in tumour angiogenesis, the 
molecular mechanisms involved in its cellular effects in 
ECs remain poorly understood.
In this investigation, we examined the role and poten-
tial cellular regulation of Gal1 in metastasis of HGSC 
to the omentum, using both in vitro studies on disease-
relevant HOMECs and immunohistochemical studies of 
patient samples. We show, for the first time that CathL, 
known to be secreted from HGSC, induces secretion 
of Gal1 from HOMECs in a transcriptionally regulated 
manner. Gal1 then acts in an autocrine manner to induce 
a proangiogenic phenotype, i.e. enhanced proliferation 
and migration, in these cells, via activation of the intra-
cellular kinases ERK1/2 and AKT. Finally, we report, for 
the first time, an increased in  vivo omental endothe-
lial expression of Gal1 that correlates with increased 
microvessel density and vessel area in omentum of 
patients with serous carcinoma (with HGSC metastasis) 
compared with normal omentum or omentum of patients 
with non-metastatic serous carcinoma, indicating a 
potential proangiogenic role for Gal1 that confirms our 
in vitro observation. These combined data strongly indi-
cate Gal1 as a proangiogenic factor in advanced HGSC 
that could be targeted therapeutically.
Materials and methods
Primary HOMEC isolation and culture
Non-malignant omental tissue samples were collected 
from patients undergoing surgery at the Royal Devon and 
Exeter NHS Foundation Trust (Exeter, United Kingdom) 
with ethical approval and informed written consent. 
HOMECs were isolated using collagen-digestion and 
anti-CD31 magnetic beads, characterised and cultured 
as primary cells as previously described [24]. Briefly, 
HOMECs were cultured in endothelial cell (EC) growth 
media (MV2, PromoCell, Heidelberg, Germany) supple-
mented with supplied growth factors, 5% (v/v) foetal calf 
serum (FCS) and 0.1% (v/v) gentamycin (Sigma, Poole, 
UK). Cells were maintained at 37  °C in a humidified 
atmosphere supplemented with 5%  CO2.
Cell based ELISA
Phosphorylation levels of NFκB, ERK1/2 and AKT were 
measured using specific cell-based ELISA kits (Bio-
Techne Ltd., Abingdon, UK) according to the manufac-
turer’s instructions. Cells were starved, and subsequently 
treated ± recombinant human VEGF165 (20 ng/ml, posi-
tive control; Peprotech, London, UK), CathL (50  ng/ml; 
from human liver; Sigma-Aldrich, Poole, UK) and recom-
binant human Gal1 (50  ng/ml; Sigma-Aldrich, Poole, 
UK) ± NFκB, ERK1/2 and AKT inhibitors at their given 
concentrations (Table 1) for 4, 10 min or 4 h. To confirm 
the effect of these inhibitors, HOMECs were pre-incu-
bated with the inhibitors and then co-treated ± proangio-
genic factors. Fluorescence intensity was measured, and 
the results were expressed as fold change in phospho-
NFκB (p65), -ERK1/2 or -AKT relative to total NFκB, 
ERK or AKT levels (compared to control).
Cell proliferation assay
WST‑1 assay
Investigation of HOMEC proliferation was as previously 
described [8]. Briefly, cells were seeded at a density of 
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1 × 104 cells per well in 2% (w/v) gelatin (Sigma, Poole, 
UK) coated 96-well plates (Greiner Bio One, Stonehouse, 
UK) and treated overnight in growth factor-deprived 
media containing 2% (v/v) FCS. After 24  h, treatments 
(1, 5, 10, 25, 50 and 125  ng/ml of Gall1 ± inhibitors) 
were added at the given concentrations (Table  1) and 
incubated for 48 or 72  h. Subsequently, WST-1 reagent 
(Roche, Welwyn Garden City, UK) was added to the assay 
medium and absorbance was measured at 450 nm against 
the blank in a PHERAstar BMG plate-reader.
BrdU assay
Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 20,000 cells/well in starvation media con-
taining 2% FCS. After overnight incubation, cells were 
treated with or without Gal1 (1, 5, 25, 50 and 125 ng/ml) 
and incubated for 48  h. A commercially available BrdU 
reagent (Merck Chemicals Ltd., Nottingham, UK) was 
added to the wells for the last 24-h incubation and cel-
lular proliferation was assessed (according to the manu-
facturer’s instructions) based on absorbance using a 
SpectraMax plate-reader (Molecular Devices, Berkshire, 
UK) set at dual wavelength of 450/550 nm.
CyQUANT assay
This procedure was performed according the manufac-
turers instruction. Briefly, after 48 h treatment with Gal1 
(50 ng/ml), media was removed from each well, followed 
by addition of the dye binding solution (1X HBSS buffer) 
containing CyQUANT NF dye reagent (Fisher Scientific, 
Loughborough, UK). After 2-h incubation, the plates 
were read at Ex/Em: 485/530 using a FLUOstar BMG 
plate-reader (BMG Labtech Ltd, Bucks, UK) and cell pro-
liferation was assessed based on the fluorescence inten-
sity against the background containing HBSS buffer.
HOMEC migration
Assessment of cellular migration was carried out using 
a Cultrex Cell 96 transwell migration assay (Bio-Techne 
Ltd., Abingdon, UK) as previously described (5). Briefly, 
cells were incubated in growth factor-deprived media 
supplemented with 0.5% FCS overnight. Next, cells were 
seeded at a density of 5 × 104 in the upper assay cham-
ber and treated ± Gal1 (50 ng/ml) and in the presence or 
absence of ERK1/2 and/or AKT inhibitors at their given 
concentrations (Table  1). Negative controls received 
carrier alone. After 6 h incubation at 37  °C, the bottom 
chambers were washed, followed by addition of cell dis-
sociation solution/calcein AM for a further hour to label 
and detach migrated cells. Fluorescence in the bottom 
wells was read at Ex/Em: 485/520 nm.
Human galectin‑1 ELISA (Bio‑Techne Ltd., Abingdon, UK)
HOMECs were treated ± CathL ± sulfasalazine (NFκB 
inhibitor, 100 µmol/l) for 4 min, 30 min, 2, 4, 8 and 24 h. 
Supernatants were collected, centrifuged at 200g for 
10 min, and transferred into fresh microfuge tubes which 
were either stored at − 20  °C for future experiments or 
immediately used to detect levels of Gal1. The assay was 
carried out according to the manufacturer’s instructions.
qRT‑PCR
Total RNA from cultured HOMECs treated with 
CathL ± sulfasalazine was isolated with TRI reagent as 
per the manufacturer’s protocol (Sigma-Aldrich, Gill-
ingham, UK). Extracted RNA was DNase-treated using a 
DNAfree kit (Ambion, Northumberland, UK). Comple-
mentary DNA (cDNA) was synthesised from 1 µg of RNA 
per sample using the qScript supermix kit (Quanta Bio-
sciences, USA). Real-time RT-PCR was conducted using 
the TaqMan PrecisionPLUS master mix (Primer Design, 
Southampton, UK) with cycling conditions as follows: 1 
Table 1 Concentrations of treatments added
n/a, Not applicable
Treatments Purpose Pre‑incubation time Concentration(s) Source
VEGF165 Positive control n/a 20 ng/ml Peprotech (London, UK)
Tumour necrosis factor-
alpha (TNF-α)
Positive control n/a 160 pg/ml Enzo Life sciences, (Exeter, UK)
CathL Treatment n/a 50 ng/ml Sigma-Aldrich (Poole, UK)
Gal1 Treatment n/a 1, 5, 10, 25, 50, 125 ng/ml Sigma-Aldrich (Poole, UK)
Sulfasalazine NFκB inhibitor 24 h 100 µmol/l Stratech (Suffolk, UK)
U0126 MEK/ERK1/2 inhibitor 20–30 min 10 µmol/l Stratech (Suffolk, UK)
PD98059 MEK/ERK1/2 inhibitor 20–30 min 25 µmol/l Stratech (Suffolk, UK)
LY294002 PI3K inhibitor 1–2 h 25 µmol/l Stratech (Suffolk, UK)
MK2206 AKT inhibitor 1–2 h 5 µmol/l Stratech (Suffolk, UK)
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cycle of 60 °C for 2 min and 95 °C for 2 min; 40 cycles of 
95 °C for 10 s, 60 °C for 30 s; and 1 cooling cycle of 37 °C 
for 30 s, on a LightCycler 96 Real-time Detection System 
(Roche, Welwyn Garden City, UK). The specificity of the 
PCR product was confirmed by melting-curve analysis. 
The Gal1, and two house-keeping genes GAPDH and 
β-2-microtubulin primers were purchased from Thermo 
Fisher Scientific (Northumberland, UK). For each gene, 
crossing point (Cp) values were determined from the 
linear region of the amplification plot and normalized 
by subtraction of the geometric mean of the Cp values 
for two housekeeping genes. Relative expression was 
subsequently calculated using the 2-ΔCp approach, and 
the data were presented as fold change in LGALS1 gene 
expression (normalised to control).
Patients
Female patients signed an informed consent form for the 
study which was reviewed by the Institutional Review 
Board (Gomel State Medical University), Gomel, Bela-
rus. Sixty formalin-fixed and paraffin embedded archival 
tissue specimens including 20 cases of each of the fol-
lowing: normal omenta (from organ transplant donors), 
omenta of serous ovarian carcinoma patients without 
omental metastasis (SC wo MTS) and, with metasta-
sis (SC w MTS), were used for immunohistochemistry 
(IHC). This was assessed by histopathologists D.A.Z. and 
S.L.A using the following criteria: a presence of papillary 
and solid pattern of tumour moderate to marked nuclear 
atypia, nuclear pleomorphism, stromal invasion, more 
than 12 mitotic figures in 10 high power fields [25]. Clini-
cal information was obtained from the patients’ medical 
records. None of the patients within the control group 
had tumours or infections, or previous peritoneal surgi-
cal operations and traumas. The group of HGSC (SC wo 
MTS) patients were selected based on the following cri-
teria: absence of secondary tumours, absence of previous 
chemotherapy treatment (intraoperative diagnostic of 
cancer), absence of previous peritoneal surgical opera-
tions and traumas, stages II–III (FIGO, 2009). The clinic-
pathologic features of the ovarian serous carcinoma cases 
used in the present study are shown in Table 2. In stage 
II, cancer cells are found in other organs within the pel-
vis but not the omentum, and thus omenta from stage II 
patients were not included in the study [26].
Immunohistochemistry
Formalin-fixed, paraffin-embedded specimens were 
cut into 5  µm-thick sections and affixed to Thermo 
Super Frost slides (Thermo Fisher Scientific, Schwerte, 
Germany) and air-dried. This was followed by dewax-
ing in xylene and rehydration with descending graded 
alcohols to water. Tissue sections were immunostained 
using BenchMark XT (Roche-Ventana Medical Sys-
tems, Inc, Tucson, Arizona, USA). Heat-induced epitope 
retrieval was performed with Ventana Cell Conditioning 
1 (Tris ethylenediaminetetraacetic acid buffer, pH 8.0) 
for 30  min on the instrument. The endogenous peroxi-
dase activity was blocked with 3% hydrogen peroxide for 
4  min. Slides were incubated with or without (negative 
control) primary antibodies (anti-Gal1, Abcam, Cam-
bridge, UK; anti-CD34, Roche-Ventana, Arizona, USA) 
for 30  min at room temperature. The subsequent reac-
tions were performed using components from UltraView 
DAB Detection Kit (Roche-Ventana, Arizona, USA), 
including incubation with universal (rabbit and mouse) 
secondary antibody (or 8 min, a biotin-free, horseradish-
peroxidase enzyme-labeled polymer, and a signal visuali-
zation by 3,3′-diaminobenzidine hydrochloride. Sections 
were then counterstained with hematoxylin [27].
Analysis of immunohistochemistry staining
Morphometrical analysis was carried out using a Nikon 
Eclipse 50i (Nikon, Japan) and NIS-Elements software 
(Nikon, Japan). To evaluate Gal1 expression, each case 
was rated according to a score that added a scale of inten-
sity of staining to the area of staining [19]. At least five 
high-power fields (HPFs) were chosen randomly, and 
endothelium of every microvessel was counted sepa-
rately. The intensity of Gal1 staining was graded on the 
following scale: 0, no staining; 1+ , mild staining; 2+ , 
moderate staining; 3+ , intense staining.
To determine microvessel density as specified by 
Weidner, any CD34 brown staining endothelial cell or 
cell cluster that was clearly separated from adjacent 
microvessels, tumour cells and other connective tissue 
was considered a single countable microvessel [28]. Vessel 
lumens, although usually present, were not necessary for 
Table 2 Clinic-pathologic characteristics of patients
Characteristics SC wo MTS group
(n = 20)
SC w MTS group
(n = 20)
Age 49.1 (41.3–57.2) 48.5 (40.1–56.4)
FIGO stage
 IIA 11 –
 IIB 9 –
 IIIA – 10
 IIIB – 10
Primary tumour grade
 Low grade 9 8
 High grade 11 12
Ascites
 Absent 19 12
 Present (> 100 ml) 1 8
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a structure to be defined as a microvessel, and red blood 
cells were not used to define a vessel lumen. Microvessels 
were determined blindly as the investigator was blinded 
to this variable. After selecting five microscopic fields of 
highest neovascularisation or hot spots, under low mag-
nification, individual microvessels were counted manu-
ally and its area was counted using function “area” [29].
Statistical analysis
Data are expressed as mean ± standard deviation (SD) 
and analysed using Mann–Whitney U test and one-way 
ANOVA test. A Spearman (r) test with Chadock scale 
were used for correlation analysis. The univariate and 
multivariate hazard ratios (HR) were estimated using 
Cox regression analysis. A p value of less than 0.05 was 
considered statistically significant. For all data, n repre-
sents the number of patients, wells or dishes tested under 
each condition and also the results from at least two pri-
mary cell populations. Statistical analysis was performed 
using SPSS Statistical Software Package (SPSS Inc, Chi-
cago, USA) and GraphPad Prism (GraphPad Software, 
California).
Results
CathL induces secretion of Gal1
Our recent data suggests a mitogen ligand-like activity 
for CathL in HOMECs [11], and our unpublished, pre-
liminary data indicates that CathL induces a differential 
expression of galectin1 (Gal1) mRNA (LGALS1) in these 
cells. Therefore, we hypothesised that CathL induces pro-
duction and secretion of Gal1. Figure  1a confirms that 
extracellular levels of Gal1 were, indeed, significantly 
increased in the presence of CathL between 30 min (two-
fold) and 8 h (5.2-fold) but returned to control levels after 
24 h treatment (Fig. 1a). The latter may reflect Gal1 deg-
radation since the protein has a reported serum half-life 
of 1.07 h [30] or re-uptake by the cells [31]. Interestingly, 
Gal1 release was not induced in HOMECs treated with 
the other HGSC-secreted factors insulin-like growth fac-
tor binding protein 7 and CathD (data not shown), sug-
gesting that Gal1 secretion may be CathL-specific.
CathL induces upregulation of Gal1 mRNA expression
As stated above CathL rapidly (within 30  min) induced 
raised levels of extracellular Gal1, possibly reflecting 
secretion from intracellular stores or cleavage of cell sur-
face Gal1 [32]. However, even greater levels of extracel-
lular Gal1 were transiently detected after 4–8  h raising 
the possibility of additional transcriptional regulation 
(Fig.  1a). This was supported by the observation that 
6  h CathL treatment also induced a transient, 1.5-fold, 
increase in LGALS1 mRNA level (p < 0.05) vs control 
(Fig. 1b) following a time course that coincided with the 
increase in extracellular Gal1 levels. These data suggested 
that CathL induced a transient increase in LGALS1 
mRNA expression, Gal1 protein production and then 
secretion in HOMECs, and thus the upstream signalling 
pathway was investigated further.
CathL induces LGALS1 expression via activation of NFκB
NFκB is a transcription factor involved in the production 
of many physiological and pathological proteins includ-
ing Gal1 [22, 33] and thus, we examined the potential 
involvement of NFκB in CathL-induced Gal1 secretion in 
HOMECs. CathL-induced secretion of Gal1 was signifi-
cantly reduced to control levels by sulfasalazine (inhibi-
tor of NFκB) after 8  h treatment (0.9-fold vs 4.8-fold 
(CathL-treatment), both normalised to control; Fig.  1c). 
These data not only suggest that CathL induces NFkB 
activation (confirmed in Fig. 1d), but that CathL induces 
transcriptional regulation of Gal1 via NFκB activation. 
This was further supported by the qRT-PCR data demon-
strating that sulfasalazine significantly reduced LGALS1 
mRNA expression in CathL-treated cells after 6 h treat-
ment (Fig. 1e). Interestingly, sulfasalazine alone increased 
LGALS1 mRNA levels in HOMECs (Fig. 1e). This could 
(See figure on next page.)
Fig. 1 CathL-induced Gal1 secretion in HOMECs is transcriptionally regulated via activation of NFκB. a Cells were seeded and starved overnight 
in media supplemented with 2% FCS. Cells were then treated ± CathL (50 ng/ml) and supernatants were collected after 4 min, 30 min, 2, 4, 8 
and 24 h treatment. A commercially available ELISA kit was used to assess the levels of extracellular Gal1 using a SpectraMax plate reader. Results 
are mean ± SD and represented as fold change in secreted Gal1 vs control. n = 4–6. b Cells were treated ± CathL (50 ng/ml) and lysed after 6 
or 24 h treatment. Real-time PCR was performed on extracted RNA using a Roche LightCycler 96 and the data were normalised to GAPDH and 
β2 M. c Gal1 secretion was assessed with or without CathL ± sulfasalazine (100 µmol/l) for 8 h and the supernates were analysed as above. d 
CathL induces activation of NFκB (p65) in HOMECs. Cells were incubated with sulfasalazine (sulf, 100 µmol/l) or media alone for 24 h and then 
treated ± CathL (50 ng/ml) or positive control TNF-α (160 pg/ml) and in the absence or presence of sulfasalazine (100 µmol/l). After 4 h treatment, 
the phosphorylated level of NFkB was assessed using a commercially available cell-based ELISA kit. Results are mean ± SD and are represented as 
fold change in phosho-NFkB relative to total NFkB (compared to control). e CathL induces an upregulation of LGALS1 gene expression via NFkB 
activation. After overnight incubation and pre-incubation, cells were treated with CathL ± sulfasalazine for 6 h and analysed for gene expression 
as above. Results are mean ± SD and are represented as fold change in LGALS1 gene expression (relative to control), n = 4. *p < 0.05, **p < 0.01 vs 
control. #p < 0.05, ##p < 0.01 vs CathL. n.s. denotes not significant
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be due to a compensatory effect whereby other transcrip-
tion factor(s), due to an inhibition of NFκB activity, may 
induce LGALS1 expression, which is also reflected in the 
protein level. These data suggest that CathL induces Gal1 
secretion in HOMECs via activation of NFκB.
Gal1 induces HOMEC proliferation via the ERK1/2 pathway, 
but not AKT
We then examined whether the extracellular Gal1 
released from HOMECs could have autocrine pro-angi-
ogenic cellular effects i.e. on proliferation and migration. 
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HOMEC proliferation was initially investigated over a 
range of Gal1 concentrations based on the concentra-
tions of Gal1 (20–80  ng/ml) released into the superna-
tant of CathL-treated ECs over 8 h (data not shown), and 
the median range concentration (30–163 ng/ml) of Gal1 
in the sera of HGSC stage I patients [19]. Since, we are 
investigating induction of angiogenesis in ECs from non-
cancerous/non-metastatic omenta, we selected concen-
trations that fell within the lower spectrum of the in vivo 
range. Gal1 significantly induced cell proliferation at all 
concentrations tested vs control (100%, WST-1 assay) 
(Fig.  2a, Table  3). Additional studies with BrdU and 
CyQUANT proliferation assay kits confirmed that 50 ng/
ml Gal1 significantly enhanced proliferation vs control 
(100%) (Fig. 2b, c). On the basis of these results and the 
levels of secreted Gal1, 50 ng/ml of Gal1 was selected for 
further experiments.
The pro-proliferative role of Gal1 in HOMECs sug-
gested possible activation of intracellular signalling path-
ways downstream of Gal1-cell surface interaction. We 
hypothesised activation of the ERK1/2 and PI3K/AKT 
pathways based on our previous publications [8, 11] in 
these cells. Gal1 treatment rapidly (< 4  min) increased 
phosphorylation of ERK1/2 (1.8-fold vs control, Fig. 2d), 
with phosphorylated levels decreasing to control levels 
after 10  min (Fig.  2e); suggesting a transient activation. 
Similar results were seen for AKT, with phosphoryla-
tion transiently increased (1.7-fold vs control; Fig. 2f, g) 
within 4  min of Gal1 treatment. The ELISA data were 
verified using specific inhibitors of ERK1/2 (U0126 and 
PD98059) and PI3K/AKT (LY294002 and MK2206) using 
previously determined concentrations (Additional file 1: 
Figure S1) [8, 11].
Since Gal1 induced activation of the ERK1/2 and PI3K/
AKT pathways, we tested the effect of inhibition of 
these pathways on Gal1-induced HOMEC proliferation. 
Both ERK1/2 inhibitors, U0126 and PD98059, signifi-
cantly reduced Gal1-induced cell proliferation (p < 0.001, 
Fig.  3a). Gal1-induced HOMEC proliferation was also 
significantly reduced by the PI3K inhibitor, LY294002 
(p < 0.001) but the selective AKT inhibitor MK2206 had 
no effect (Fig. 3b, discussed later).
Gal1 induces migration in HOMECs
A second key element of angiogenesis is EC migration 
and thus, the pro-migratory effect of Gal1 and the path-
ways involved were examined using inhibitors of ERK1/2 
and AKT as above. Interestingly, although Gal1 sig-
nificantly induced HOMEC migration (163.4 ± 47.2% vs 
control, 100%) none of the inhibitors tested significantly 
reduced this (Fig.  4a, b). These data combined with the 
ELISA data (Additional file  1: Figure S1) suggest that 
Gal1-induced HOMEC migration may not solely depend 
on the activation of the ERK1/2 and AKT pathways, and 
that other kinases may be involved.
High positive correlation between in vivo Gal1 
expression and number and area of vessels—a potential 
proangiogenic role for Gal1 in HOMECs
The in vitro data presented above suggest that HOMEC-
secreted Gal1 may play a role in pro-angiogenic changes 
in the omental microvasculature. To examine this further 
in human disease we immunohistochemically investi-
gated expression of Gal1 protein levels in the microvas-
cular endothelium in patient samples; specifically, in 
normal omenta (control), omenta with HGSC metastasis 
(SC w MTS) and omenta with no metastatic tumour (SC 
wo MTS).
Interestingly, although the microvessels stained posi-
tively for Gal1 in all groups (Fig. 5a), the intensity of Gal1 
expression (designated 1–3, see supplementary methods 
and [19]) differed between the groups. In the control, SC 
wo MTS and SC w MTS groups, Gal1 mean scores were 
1.32 ± 0.29, 1.42 ± 0.37 and 2.39 ± 0.28 respectively with 
statistically significant differences (p < 0.001) between the 
control and the SC w MTS group, and the SC wo MTS 
and SC w MTS groups (Fig. 5b).
Fig. 2 Gal1 induces HOMEC proliferation and activation of ERK1/2 and AKT. Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000 cells/well in starvation media containing 2% FCS. a–c After overnight incubation, cells were treated ± Gal1 at various concentrations 
and incubated for 48 h. a WST-1 assay was used to assess cellular proliferation based on absorbance using a PHERAstar BMG plate-reader at 
450 nm (n = 20). b Cell proliferation was examined at 50 ng/ml of Gal1 (CyQUANT). A commercially available CyQUANT reagent was used to 
assess cell proliferation after 48 h treatment based on fluorescence intensity using a FLUOstar BMG plate-reader at Ex/Em: 485/530 nm (n = 20). 
c A commercially available BrdU reagent was added to the wells for the last 24 h incubation and cellular proliferation was assessed (according to 
the manufacturer’s instructions) at 48 h based on absorbance using a SpectraMax plate-reader at 450/550 nm (n = 15). Results are mean ± SD and 
shown as percentage of the control, **p < 0.01 and ***p < 0.001 vs control (100%). After overnight incubation, cells were treated ± 50 ng/ml of Gal1 
or 20 ng/ml of VEGF and incubated for 4 or 10 min. ERK1/2 (d, e) and AKT (f, g) phosphorylation was examined after 4 min (d, f) and 10 min (e, g) 
treatments. Commercially available cell-based ELISAs were used for the determination of ERK1/2 and AKT (S473) phosphorylation level. The ELISA 
experiments were carried out in quadruplets on two cell batches. The data show fold change in phosho-ERK1/2/AKT relative to total ERK1/2/AKT 
(compared to control). Results are mean ± SD, n.s., *p < 0.05, **p < 0.01 vs control (dotted lines); n = 4–6. n.s. denotes not significant vs control
(See figure on next page.)
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Additionally, we investigated microvessel density (as 
assessed by CD34 staining of the endothelium), a meas-
ure of vascularisation i.e. angiogenesis, in each group 
(Fig.  5a). There was a significant increase (p < 0.001) in 
vessel density in the SC w MTS group compared with 
both the control and SC wo MTS groups (Fig. 5c), con-
firming a significant increase in microvessel density in 
the omenta invaded by tumour. No non-specific stain-
ing was observed in our negative controls of each group 
(Additional file 2: Figure S2).
a b
c d
e f g
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We also measured area of vessels (per 1  mm2) and 
found a significant increase in microvessel area (p < 0.001) 
in the SC w MTS group compared with SC w/o MTS and 
control groups (Fig. 5d).
An association study revealed a positive correla-
tion between Gal1 and number of vessels (Spearman 
coefficient, r = 0.8702, p < 0.001), and area of vessels 
(r = 0.7283, p < 0.001) (Fig.  5e), suggesting a potential 
proangiogenic role for Gal1 in the omentum of advanced 
ovarian carcinoma.
Univariate Cox regression analysis of prognosis fac-
tors showed a significant association between predictive 
patient survival and Gal1 expression (p < 0.001) and num-
ber of vessels (p = 0.032), but not area of vessels (Fig. 5f ); 
possibly due to atypical vessels—a phenomenon seen 
in tumour invasion. Interestingly, in multivariate Cox 
regression analysis only Gal1 expression (p < 0.001) (but 
not area or number of vessels) demonstrated significant 
prognostic value in ovarian cancer patients (Fig. 5g), sug-
gesting that Gal1 expression could be a prognostic factor 
in advanced ovarian cancer with a role in angiogenesis. 
These data all strongly support a proangiogenic role for 
Gal1 in HGSC metastasis to the omentum.
Discussion
Treatment of HGSC remains challenging due to late 
diagnosis and limited effective therapeutic strategies for 
advanced metastatic disease. This is compounded by 
the lack of understanding of the molecular mechanisms 
involved in the establishment and growth of the metas-
tases; in particular the angiogenic activators that trans-
form the local, host microvascular endothelium into a 
pro-angiogenic state. Targeting this process is an attrac-
tive therapeutic strategy. Indeed, previous therapies have 
concentrated on disruption of the VEGF pro-angiogenic 
pathway e.g. bevacizumab. However, these strategies have 
had disappointing results [3–7], highlighting the need to 
identify new potential targets for HGSC e.g. alternative 
proangiogenic factors.
One of the major sites of HGSC metastasis is the 
omentum and, we have previously reported that omental 
Table 3 Summary of  the  pro-proliferative effect of  Gal1 on  HOMECs at  various concentrations (WST1 assay) (shown 
in Fig. 3a)
HOMECs were ± increasing concentrations of Gal1 for 48 h. Results are mean ± SD and shown as percentage of control (100%). n = 11–20
Ctrl% HOMEC proliferation (as  % of control) at each Gal1 concentration (ng/ml)
1 5 10 25 50 125
48 h 100 119.7 ± 18.7 123.8 ± 14.8 132.3 ± 13.6 113.2 ± 13.7 128.9 ± 12.2 125.9 ± 22.4
a
b
Fig. 3 Gal1 induced HOMEC proliferation via the ERK1/2 and PI3K 
pathways, but not AKT pathway. Cells were seeded in 2% gelatin 
pre-coated 96 well plates at a density of 10,000 cells/well in starvation 
media containing 2% FCS. After overnight incubation, cells were 
treated ± Gal1 (50 ng/ml) and in the absence or presence of a U0126 
(10 µmol/l) and PD98059 (25 µmol/L), b LY294002 (25 µmol/l) and 
MK2206 (5 µmol/l) and incubated for 72 h. Commercially available 
WST-1 assay was used to assess cellular proliferation. Results are 
mean ± SD and shown as percentage of the control, ***p < 0.001 vs 
control (100%), ###p < 0.001 vs Gal1 (normalised to control 100%), 
n = 14–15. n.s. denotes not significant
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angiogenesis during metastasis of HGSC may occur 
independently of the VEGF/VEGFR axis. Specifically, 
we showed that CathD and CathL, two HGSC-secreted 
enzymes, significantly induced proangiogenic endothe-
lial responses in omental ECs (HOMECs) [8, 11]. Here 
we show that CathL may induce secretion of Gal1 from 
HOMECs which acts as an autocrine pro-angiogenic 
factor in the local microvasculature, contributing to sec-
ondary tumour growth. One important aspect of these 
studies is the use of omental microvascular ECs. Since 
ECs display heterogeneity in their proteomics, morphol-
ogy and functionality, it is essential to undertake studies 
using cells from a relevant vascular bed.
Gal1 has been shown to be involved in tumour pro-
gression, development and angiogenesis [21, 23]. How-
ever, a role for CathL-induced extracellular Gal1 in 
HGSC metastasis is a novel finding. The observation that 
CathL-induced increases in extracellular Gal1 levels were 
detected within 30  min suggests release from cytoplas-
mic stores [12, 32]. The enhanced CathL-induced cellu-
lar release of Gal1 at 4 and 8  h suggested an additional 
transcriptional regulation of LGALS1 which was con-
firmed by increased expression of LGALS1 with CathL 
treatment. Although CathL has not previously been 
reported to induce expression of LGALS1 or secre-
tion of Gal1, transcriptional regulation of Gal1 has been 
reported in ECs, specifically, LDL-induced expression of 
Gal1 in human aortic ECs [34].
CathL significantly enhanced NFkB phosphoryla-
tion and the NFkB inhibitor, sulfasalazine, significantly 
reduced this phosphorylation as well as LGALS1 expres-
sion and Gal1 secretion, supporting a role for NFkB in 
CathL-induced Gal1 secretion. We reported previously 
that CathL acts non-proteolytically on these cells and 
induces proangiogenic changes. Thus, it is possible that 
CathL binds to an, as yet, unidentified receptor and 
induces this pathway.
Next, we showed that Gal1 acted as a potent pro-
angiogenic factor in HOMECs, stimulating both prolif-
eration and migration; an observation that agrees with 
other findings showing pro-proliferative effects of exog-
enous Gal1 in human ECs [23, 31]. We then investigated 
a b
Fig. 4 Gal1 does not induce HOMEC migration via the ERK1/2 or PI3K/AKT pathway. HOMECs were seeded in the upper transwell chamber and 
treated ± Gal1 (50 ng/ml) in the absence or presence of ERK1/2 inhibitors a U0126 (10 µmol/l) and PD98059 (25 µmol/l), or PI3K and AKT inhibitors 
b LY294002 (25 µmol/l) and MK2206 (5 µmol/l) respectively in media containing 0.5% FCS. The lower well contained corresponding treatments. 
After 6 h, migrated cells were stained with calcein AM and fluorescence was quantified by using a FLUOstar plate reader at Ex/Em: 485/520. Results 
are mean ± SD and shown as percentage of the control, *p < 0.05, **p < 0.01, ***p < 0.001 vs control (100%), n = 4–11. n.s. denotes not significant
(See figure on next page.)
Fig. 5 High positive correlation between Gal1 expression and number of vessels, and area of vessels. a Expression of Gal1 (upper panel) and 
CD34 (lower panel) in endothelium (moderate expression- red arrows) in control (left), SC wo MTS (serous carcinoma without omental metastasis, 
moderate expression; middle), and SC w MTS (serous carcinoma with omental metastasis, high expression; right). In SC w MTS, Gal1 expression is 
shown in endothelium (red arrows), cancer cells (orange arrows) and stromal lymphocytes infiltration (yellow arrows). b Significantly higher Gal1 
expression in SC w MTS group compared to control and SC wo MTS. Gal1 expression is represented as an intensity score, as described by Chen 
et al. [19]. c A significant increase in the number of vessels and d area of vessels were found in SC w MTS group compared to the other groups. 
The vessels were counted according to Weidner’s method described in “Materials and method” section [28]. e Very high correlation between Gal1 
and number, and area of vessels, indicating a potential proangiogenic role for Gal1. f Univariate and g multivariate hazard ratios of Cox analysis 
of predictive patients’ survival. Photographs were taken using a Nikon Eclipse 50i. ***p < 0.001 vs control group, ###p < 0.001 vs SC wo MTS. n.s. 
denotes not significant. Magnification: ×200
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the potential signalling pathways activated downstream 
by Gal1; concentrating on two key signalling molecules 
ERK1/2 and AKT. Gal1 induced significant and transient 
phosphorylation of both, an effect which was abolished 
by inhibitors of MEK1/2 (upstream of ERK1/2, U0126 
and PD98059) and PI3K/AKT (LY294002 and MK2206). 
Gal1-induced HOMEC proliferation was significantly 
reduced by the two MEK1/2 inhibitors and the PI3K 
inhibitor LY294002, but not the selective AKT inhibitor 
MK2206. It is possible that the latter result was observed 
due to cross-reactivity of LY294002 with the ERK1/2 
pathway and thus inhibition of ERK1/2 phosphorylation 
[35]. Taken together, our data suggest that ERK1/2 path-
way is involved in the HOMEC proliferation induced by 
exogenous Gal1 (Fig. 6).
Gal1 also had a potent pro-migratory effect on 
HOMECs. However, this was not impacted by the 
ERK1/2 or AKT inhibitors despite previous reports that 
these kinases are involved in cell migration [8, 11]. In ECs 
Thijssen et  al. [31] previously suggested involvement of 
activated ERK1/2 in Gal1-induced HUVEC migration, 
however Hsieh et al. [36], reported that activated JNK, a 
Fig. 6 A summary of the proposed CathL-induced Gal1 secretion pathway and its pro-proliferative function and potential therapeutic targets in 
HOMECS. 1. CathL non-proteolytically activates a cell surface receptor, possibly a receptor tyrosine kinase, which leads to an increase in activated 
levels of the transcription factor NFκB, resulting in increased expression of LGALS1 (Gal1 mRNA). Sulfasalazine, an inhibitor of NFκB, reduces LGALS1 
expression and subsequent secreted level of Gal1. 2. LGALS1 is transcribed and translated into Gal1 which is secreted out of the cell, possibly 
utilising a  Na+/K+ ATP-pump, via a non-conventional secretory pathway. 3. Secreted Gal1 induces activation of MAP kinase ERK1/2 and PI3K/AKT via 
an autocrine mechanism and an unknown receptor(s), where the ERK1/2 pathway induces HOMEC proliferation. The MEK/ERK1/2 inhibitors U0126 
and PD98059 significantly reduce this cellular function by inhibiting ERK1/2 phosphorylation. Both the PI3K inhibitor LY294002 and AKT inhibitor 
MK2206 inhibit phosphorylation of AKT at Ser473 (S473) in Gal1-treated HOMECs. However, only LY294002, but not MK2206, inhibits Gal1-induced 
HOMEC proliferation, suggesting a cross-reactivity of PI3K inhibitor LY294002 with the ERK1/2 pathway. Potential therapeutic targets are: Gal1 
secretory mechanism, Gal1 binding to its receptor(s), and blocking receptor(s) for Gal1. N, nucleus; C, cytoplasm
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MAP kinase, is responsible for Gal1-induced migration 
in HUVECs, highlighting the potential involvement of 
other kinases in HOMEC migration.
We then carried out immunohistochemical analysis 
of patient samples to complement the in  vitro studies. 
Although adipocytes are known to express Gal1 on their 
cell membrane [37], strikingly, there was a significant 
increase in Gal1 expression in the microvessel endothe-
lium and surrounding stromal cells in the omenta with 
metastatic serous carcinoma compared with normal or 
non-metastatic serous carcinoma omenta, with a strong 
positive correlation between Gal1 staining intensity and 
both microvessel number and vessel area. A significant 
Gal1 expression and its role in angiogenesis and metas-
tasis has also been reported in cancer-associated stroma 
in primary ovarian tumour, breast and pancreatic cancers 
[38–40]. Here, we show high-intensity Gal1 expression 
in cancer-associated stroma in secondary lesions for the 
first time in the metastasised omenta. These data, sup-
port the possibility that Gal1 is a potent proangiogenic 
factor in HGSC. Since we previously showed increased 
endothelial expression of CathL in the omenta of patients 
with metastasised serous carcinoma [41], the current 
observation of a similar increased Gal1 expression pat-
tern in comparable patient samples could signify a physi-
ological role for CathL induction of Gal1 expression in 
angiogenesis in this pro-metastatic disease.
We also demonstrated a significant association 
between increased Gal1 expression and a poor predictive 
survival for HGSC patients. Interestingly, Schulz and col-
leagues reported that overexpression of Gal1 was asso-
ciated with increased migratory and invasive behaviour, 
and decreased sensitivity to cisplatin, in HGSC cells; pos-
sibly explaining the decreased survival of HGSC patients 
with increased Gal1 expression [42].
In summary, our data suggest that the HGSC-secreted 
factor CathL induces secretion of Gal1 from HOMECs 
which, via an autocrine mechanism, stimulates pro-angi-
ogenic cellular responses i.e. proliferation and migration 
in the omental vasculature during metastasis of HGSC.
Our observation that Gal1 may play an important pro-
angiogenic role is supported by previous reports indi-
cating a role for Gal1 in tumour progression, partly by 
triggering angiogenesis [20]. For instance, in  vitro, ele-
vated Gal1 induced HUVECs to migrate and proliferate 
and in in vivo studies, Gal1 knockout mice had severely 
compromised tumour growth and vessel density [21]. In 
a variety of cancers including prostate, colon and thy-
roid [17], Gal1 is highly expressed in cancer-associated 
stroma, and this over-expression correlates with patho-
logical factors including advanced disease stage, tumour 
invasion and increased rates of disease reoccurrence 
[19]. Over-expression of Gal1 has also been found to 
increase tumour cell invasion in the OVCAR-3 cell line 
[19]. Moreover, when the serum levels of Gal1 were 
compared in ovarian cancer patients alongside the most 
widely used biomarker CA125, it was found that around 
70% of patients were correctly identified as positive by 
both proteins [19], suggesting that Gal1 could potentially 
be used as a biomarker for HGSC progression, as well as 
outcome.
Conclusions
Identification of new targets is a priority in advanced 
HGSC. Our data indicate a strong proangiogenic effect 
of Gal1 on omental ECs, with high positive correlation 
between Gal1 and microvessel density in vivo, highlight-
ing that the Gal1 pathway could be a potential therapeu-
tic target in HGSC metastasis to the omentum. Although 
anginex, a non-specific anti-angiogenic compound, has 
been shown to reduce angiogenesis by binding and pos-
sibly blocking cell membrane-bound Gal1 [21, 43], there 
is currently no FDA-approved therapy in place to block 
potent effects of secreted Gal1. However, there are a 
number of potential Gal1-related cellular targets [44] 
(Fig. 6), for instance, the secretory pathway of Gal1 and 
potential Gal1-binding receptors that could potentially 
be targeted in the quest to find an effective treatment for 
metastasised HGSC.
Additional files
Additional file 1: Figure S1. Inhibitors of ERK1/2 and AKT reduce ERK1/2 
and AKT phosphorylation respectively in intact HOMECs. After overnight 
incubation in starvation media (containing 2% FCS), cells were pre-
incubated with the ERK1/2 inhibitors a) U0126 (10 μmol/l) and PD98059 
(25 μmol/l) or PI3K/AKT inhibitors b) LY294002 (25 μmol/l) and c) MK2206 
(5 μmol/l) for (a) 20–30 min or (b+ c) 2.5 h, and then co-treated with or 
without 50 ng/ml of Gal1 or 20 ng/ml of VEGF for 4 min. Commercially 
available cell-based ELISAs were used for determination of phosphoryla-
tion levels. The data show fold change in phospho-protein relative to total 
protein (compared to control). Results are mean ± SD, *p<0.05, **p<0.01 
vs control (1-fold, dotted lines), #p<0.05 vs VEGF/Gal1 (normalised to 
control), n = 4.
Additional file 2: Figure S2. Tissue sections were stained only with 
secondary antibody to both Gal1 and CD34 in control group, groups with 
serous carcinoma without metastasis (SC wo MTS) and with metastasis (SC 
w MTS). Photographs were taken using a Nikon Eclipse 50i. Magnification 
×200.
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